8 years ago

SuperX Raises $11 Million to Develop Anticoagulant Antibodies

  • SuperX Ltd, a UK-based biopharmaceutical company, has secured $11 million in Series A funding led by Medicxi with participation from Johnson & Johnson Innovation – JJDC, Inc

  • The funding will be used to advance the development of SuperX's anticoagulant antibody therapies

  • SuperX is a virtual company, leveraging external partners for drug discovery and development, primarily based in the Babraham Research Campus near Cambridge.

      • ProblemHealthcare

      "Current anticoagulant drugs are often ineffective and can cause serious side effects, like bleeding."

      Solution

      "SuperX is developing new antibodies with anticoagulant properties that are more effective and have fewer side effects."

      Covered on